+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Huntington Disease - Pipeline Review, H1 2020

  • ID: 5130311
  • Drug Pipelines
  • June 2020
  • Region: Global
  • 390 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AcuraStem Inc
  • Brainvectis SAS
  • F. Hoffmann-La Roche Ltd
  • Neurodon LLC
  • Primary Peptides Inc
  • Shinkei Therapeutics LLC
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease - Pipeline Review, H1 2020, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 13, 62, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 3 molecules, respectively.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AcuraStem Inc
  • Brainvectis SAS
  • F. Hoffmann-La Roche Ltd
  • Neurodon LLC
  • Primary Peptides Inc
  • Shinkei Therapeutics LLC
  • MORE
  • Introduction
  • Huntington Disease - Overview
  • Huntington Disease - Therapeutics Development
  • Huntington Disease - Therapeutics Assessment
  • Huntington Disease - Companies Involved in Therapeutics Development
  • Huntington Disease - Drug Profiles
  • Huntington Disease - Dormant Projects
  • Huntington Disease - Discontinued Products
  • Huntington Disease - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Huntington Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Huntington Disease - Pipeline by Acen Regenerative Medicine Sci-Tech Co Ltd, H1 2020
  • Huntington Disease - Pipeline by AcuraStem Inc, H1 2020
  • Huntington Disease - Pipeline by Adeptio Pharmaceuticals Ltd, H1 2020
  • Huntington Disease - Pipeline by AFFiRiS AG, H1 2020
  • Huntington Disease - Pipeline by Alkermes Plc, H1 2020
  • Huntington Disease - Pipeline by Allianz Pharmascience Ltd, H1 2020
  • Huntington Disease - Pipeline by Alsonex Pty Ltd, H1 2020
  • Huntington Disease - Pipeline by Anima Biotech Inc, H1 2020
  • Huntington Disease - Pipeline by Annexon Inc, H1 2020
  • Huntington Disease - Pipeline by Armgo Pharma Inc, H1 2020
  • Huntington Disease - Pipeline by ArunA Biomedical Inc, H1 2020
  • Huntington Disease - Pipeline by Asdera LLC, H1 2020
  • Huntington Disease - Pipeline by Asklepios BioPharmaceutical Inc, H1 2020
  • Huntington Disease - Pipeline by Avergen Pharmaceuticals GmbH, H1 2020
  • Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H1 2020
  • Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2020
  • Huntington Disease - Pipeline by Brainvectis SAS, H1 2020
  • Huntington Disease - Pipeline by Celon Pharma SA, H1 2020
  • Huntington Disease - Pipeline by Chaperone Pharma BV, H1 2020
  • Huntington Disease - Pipeline by Chaperone Therapeutics Inc, H1 2020
  • Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2020
  • Huntington Disease - Pipeline by Cleave Therapeutics Inc, H1 2020
  • Huntington Disease - Pipeline by Collaborative Medicinal Development LLC, H1 2020
  • Huntington Disease - Pipeline by Curyx Bio Inc, H1 2020
  • Huntington Disease - Pipeline by DanPET AB, H1 2020
  • Huntington Disease - Pipeline by Dystrogen Therapeutics SA, H1 2020
  • Huntington Disease - Pipeline by Emerald Health Sciences Inc, H1 2020
  • Huntington Disease - Pipeline by Enzerna Biosciences LLC, H1 2020
  • Huntington Disease - Pipeline by Evotec SE, H1 2020
  • Huntington Disease - Pipeline by Exicure Inc, H1 2020
  • Huntington Disease - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2020
  • Huntington Disease - Pipeline by Hope Biosciences LLC, H1 2020
  • Huntington Disease - Pipeline by Immungenetics AG, H1 2020
  • Huntington Disease - Pipeline by InnoMedica Holding AG, H1 2020
  • Huntington Disease - Pipeline by Krisani Bio Sciences Pvt Ltd, H1 2020
  • Huntington Disease - Pipeline by Living Cell Technologies Ltd, H1 2020
  • Huntington Disease - Pipeline by Locana Inc, H1 2020
  • Huntington Disease - Pipeline by Medesis Pharma SA, H1 2020
  • Huntington Disease - Pipeline by MindImmune Therapeutics Inc, H1 2020
  • Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2020
  • Huntington Disease - Pipeline by Mitoconix Bio Ltd, H1 2020
  • Huntington Disease - Pipeline by Mitokinin LLC, H1 2020
  • Huntington Disease - Pipeline by MMJ International Holdings Corp, H1 2020
  • Huntington Disease - Dormant Projects, H1 2020
  • Huntington Disease - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Huntington Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3
  • Acen Regenerative Medicine Sci-Tech Co Ltd
  • AcuraStem Inc
  • Adeptio Pharmaceuticals Ltd
  • AFFiRiS AG
  • Alkermes Plc
  • Allianz Pharmascience Ltd
  • Alsonex Pty Ltd
  • Anima Biotech Inc
  • Annexon Inc
  • Armgo Pharma Inc
  • ArunA Biomedical Inc
  • Asdera LLC
  • Asklepios BioPharmaceutical Inc
  • Avergen Pharmaceuticals GmbH
  • Azevan Pharmaceuticals Inc
  • BrainStorm Cell Therapeutics Inc
  • Brainvectis SAS
  • Celon Pharma SA
  • Chaperone Pharma BV
  • Chaperone Therapeutics Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Cleave Therapeutics Inc
  • Collaborative Medicinal Development LLC
  • Curyx Bio Inc
  • DanPET AB
  • Dystrogen Therapeutics SA
  • Emerald Health Sciences Inc
  • Enzerna Biosciences LLC
  • Evotec SE
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Genervon Biopharmaceuticals LLC
  • Hope Biosciences LLC
  • Immungenetics AG
  • InnoMedica Holding AG
  • Krisani Bio Sciences Pvt Ltd
  • Living Cell Technologies Ltd
  • Locana Inc
  • Medesis Pharma SA
  • MindImmune Therapeutics Inc
  • Mitochon Pharmaceuticals Inc
  • Mitoconix Bio Ltd
  • Mitokinin LLC
  • MMJ International Holdings Corp
  • NeuBase Therapeutics Inc
  • NeuExcell Therapeutics Inc
  • Neurimmune Holding AG
  • Neurodon LLC
  • NeuroNascent Inc
  • New World Laboratories Inc
  • NLS Pharma Group
  • Novartis AG
  • Nuredis Inc
  • Omeros Corp
  • Ophidion Inc
  • Oryzon Genomics SA
  • Oscine Therapeutics
  • Oxalys Pharmaceuticals Inc
  • PharmatrophiX Inc
  • Prilenia Therapeutics Development Ltd
  • Primary Peptides Inc
  • ProQR Therapeutics NV
  • Prous Institute for Biomedical Research SA
  • PTC Therapeutics Inc
  • reMYND NV
  • ReNeuron Group Plc
  • Resilio Therapeutics LLC
  • Retrotope Inc
  • Sage Therapeutics Inc
  • Secura Bio Inc
  • Seneb BioSciences Inc
  • Shinkei Therapeutics LLC
  • SOM Biotech SL
  • Sosei Heptares
  • Spark Therapeutics Inc
  • Stealth BioTherapeutics Corp
  • Suven Life Sciences Ltd
  • T3D Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • TreeFrog Therapeutics SAS
  • Ultragenyx Pharmaceutical Inc
  • UniQure NV
  • Vaccinex Inc
  • Vitality Biopharma Inc
  • Vivoryon Therapeutics AG
  • Voyager Therapeutics Inc
  • Vybion Inc
  • Wave Life Sciences Ltd
Note: Product cover images may vary from those shown
Adroll
adroll